CurrentColorado Rocky Mountain Health PlansPolicy 2025D0044P

Hereditary Angioedema (HAE), Treatment and Prophylaxis – Commercial Medical Benefit Drug Policy

Medical benefit drug policy describing coverage rationale, initial and continuation medical necessity criteria, limitations, and applicable HCPCS/J-codes for select HAE products (Berinert, Ruconest, Kalbitor, Cinryze). This is part 1 of 2 and includes clinical background, evidence summaries, society guidelines, and referenced codes.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyHereditary Angioedema (HAE), Treatment and Prophylaxis – Commercial Medical Benefit Drug Policy

Policy CodePolicy 2025D0044P

Change TypeNo material change

Effective DateNov 1, 2025

Next Review Date

Key ActionProvide laboratory documentation of C1‑INH antigenic or functional level below the lower limit of normal OR genetic testing confirming relevant variants OR documentation of recurring angioedema refractory to high‑dose antihistamines with confirmed family history.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes.

4Drugs specifically addressed (Berinert, Ruconest, Kalbitor, Cinryze)

3Medications FDA-labeled for acute HAE treatment in this policy

1Medication with mixed plan stance (Cinryze)

Coverage summary & stance

Policy 2025D0044P effective 2025-11-01 addresses four HAE products: Berinert, Ruconest, Kalbitor, and Cinryze and takes a mixed coverage stance. Berinert, Ruconest, and Kalbitor are supported for acute HAE treatment when specified criteria are met (diagnosis confirmation, specialist prescribing, not used in combination with other acute therapies, and programmatic documentation/self-administration attestations as applicable).

Cinryze has a mixed position across plans: under Medical Necessity plans Cinryze is stated as not medically necessary for treatment of HAE (published evidence does not demonstrate superiority vs other C1-INH products), while under Non‑Medical Necessity plans Cinryze is proven for prophylaxis when used for prophylaxis and not combined with other prophylactic products.

The policy is a medical benefit drug policy (part of a two‑part series) that defines initial and continuation medical necessity criteria, documentation and prior‑authorization requirements, applicable HCPCS J‑codes (J0596, J0597, J0598, J1290), and limits authorizations to no more than 12 months for initial and reauthorization periods.

Initial therapy — medical necessity criteria for acute HAE treatment

Medically necessary — Treatment of acute HAE attacks (Berinert, Ruconest, Kalbitor)

Covered when ALL of the following are met:

ALL of the following

Diagnosis confirmation
- C1-INH deficiency/dysfunction (Type I or II HAE) documented by one of
  - C1 inhibitor (C1-INH) antigenic level below the lower limit of normal
  - C1-INH functional level below the lower limit of normal
- OR normal C1-INH levels with one of
  - Confirmed presence of variant(s) in gene(s) for factor XII, angiopoietin-1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-O-sulfotransferase 6
  - Recurring angioedema attacks that are refractory to high-dose antihistamines with confirmed family history of angioedema
Used for treatment of an acute HAE attack
Not used in combination with other approved treatments for acute HAE attacks (e.g., Berinert, Firazyr, Kalbitor or Ruconest)
Prescribing specialist
- Prescribed by an Immunologist
- Prescribed by an Allergist
Berinert-specific prior therapy: For Berinert requests only: submission of medical records documenting a history of failure, contraindication, or intolerance to Ruconest (C1 esterase inhibitor recombinant)
Self-administration attestation: For Berinert and Ruconest requests only: physician attestation that the patient is unable to self-administer or there is no competent caregiver to administer the drug
Authorization duration: Initial authorization will be for no more than 12 months

Continuation therapy — medical necessity criteria

Medically necessary — Continuation of therapy (Berinert, Ruconest, Kalbitor)

Covered when ALL of the following are met:

ALL of the following

Documentation of positive clinical response
Used for treatment of an acute HAE attack
Not used in combination with other approved treatments for acute HAE attacks (e.g., Berinert, Firazyr, Kalbitor or Ruconest)
Prescribing specialist
- Prescribed by an Immunologist
- Prescribed by an Allergist
Self-administration attestation (Berinert/Ruconest): For Berinert and Ruconest requests only: physician attestation that the patient is unable to self-administer or there is no competent caregiver to administer the drug
Reauthorization duration: Reauthorization will be for no more than 12 months

Cinryze — plan-specific medical necessity statements

Cinryze — Medical necessity statements

ANY of the following

Medical Necessity Plans: Cinryze is NOT medically necessary for the treatment of hereditary angioedema (HAE). Published clinical evidence does not demonstrate superiority in the efficacy and safety of Cinryze to other available C1-esterase inhibitors (e.g., Berinert, Haegarda).
Non-Medical Necessity Plans: Cinryze is proven for the treatment of hereditary angioedema (HAE) when BOTH of the following are met: used for prophylaxis against HAE attacks; and not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Haegarda, Takhzyro).

Provider actions, documentation & prior authorization requirements

Documentation Required

Diagnosis documentation

Require laboratory documentation of C1-INH antigenic or functional level below the lower limit of normal OR genetic testing confirming relevant variants OR documentation of recurring angioedema refractory to high-dose antihistamines with confirmed family history.

Prior Authorization

Specialist prescribing requirement

Therapy must be prescribed by an Immunologist or Allergist for both initial and continuation approvals.

Documentation Required

Berinert prior therapy / self-administration attestation

For Berinert requests submit medical records documenting a history of failure, contraindication, or intolerance to Ruconest. For Berinert and Ruconest requests provide a physician attestation that the patient is unable to self-administer or there is no competent caregiver to administer the drug.

J0596
J0597

Prior Authorization

Authorization duration

Initial and reauthorization approvals are limited to no more than 12 months.

Applicable codes

Applicable J-codesHCPCS

J0596	Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units
J0597	Injection, C-1 esterase inhibitor (human), Berinert, 10 units
J0598	Injection, C1 esterase inhibitor (human), Cinryze, 10 units
J1290	Injection, ecallantide, 1 mg

Relevant diagnosis code (examples provided)ICD-10

D84.1

Defects in the complement system

Clinical evidence summary

1000 UCinryze prophylaxis dosing: 1000 U twice weekly supported by trials

n=22,146Cinryze evidence: randomized cross‑over n=22; extension n=146 showing reduced attack rates

94%→70%Twice‑weekly response: favorable rate ~95.7% at 30 days to 70.7% at 120 days (extension data)

Ruconest — Riedl open‑label: an open‑label North American study (n=62 patients, 168 attacks) treated with IV 50 U/kg (option for repeat dose) reported median time to beginning of symptom relief of 37–67 minutes for first five attacks and >90% of attacks responded within 4 hours; repeated dosing showed continued efficacy and acceptable safety.

Ruconest — Phase 3 RCT: a randomized, placebo‑controlled trial (n=75) found median time to beginning of symptom relief 90 min with rhC1INH versus 152 min with placebo (p=0.031); VAS measures showed benefit (75 vs 303 min, p=0.003) and no thromboembolic events or neutralizing antibodies reported.

Berinert — IMPACT trials and extensions: IMPACT‑1 (randomized controlled) demonstrated that 20 U/kg improved median time to onset of symptom relief vs placebo (0.5 vs 1.5 hours; p=0.0025) and IMPACT‑2 and long‑term analyses (1085 attacks in 57 patients) showed consistent responses with repeated 20 U/kg dosing and no inhibitory anti‑C1‑INH antibodies.

Kalbitor (ecallantide) — EDEMA trials: double‑blind, placebo‑controlled studies (EDEMA‑3/EDEMA‑4 and pooled analyses) demonstrated significant symptom reduction at 4 hours vs placebo with maintained benefit through 24 hours; primary endpoints (MSCS, TOS) favored ecallantide and analyses showed low likelihood of clinically meaningful rebound/relapse.

Cinryze — Prophylaxis trials: a randomized, double‑blind, placebo‑controlled crossover trial (n=22) and an open‑label extension (n=146) support prophylactic dosing of 1000 U twice weekly, showing significantly reduced attack rates (e.g., 6.26 vs 12.73 attacks per 12‑week period in crossover trial) and large reductions in monthly attack rates in the extension (≈93.7% reduction).

Overall evidence context: randomized controlled and well‑conducted trials support efficacy of recombinant and plasma‑derived C1‑INH products and ecallantide for acute HAE treatment; Cinryze has randomized and extension data supporting prophylaxis but is not shown superior to other C1‑INH products for treatment in some plan types.

Background & definitions

Pathophysiology: Hereditary angioedema (HAE) due to C1‑INH deficiency/dysfunction leads to dysregulation of the contact (intrinsic coagulation) and kallikrein–kinin systems with excessive generation of bradykinin, a vasodilator that increases vascular permeability and produces the characteristic localized swelling and pain of HAE attacks.

Human C1‑INH (Berinert, Cinryze): plasma‑derived C1 esterase inhibitors are highly purified human proteins that replace deficient or dysfunctional C1 inhibitor, restoring regulation of complement, contact, and fibrinolytic pathways by inactivating plasma kallikrein and factor XIIa and thereby preventing bradykinin formation; Cinryze increases antigenic and functional plasma C1‑INH levels, and Berinert replaces the missing/malfunctioning protein for intravenous treatment.

Recombinant C1‑INH (Ruconest): rhC1INH is a serine protease inhibitor that irreversibly binds and inactivates proteases such as kallikrein and factor XIIa, suppressing complement and contact pathway activation and preventing bradykinin generation to reduce vascular permeability during attacks.

Plasma kallikrein inhibitor (Kalbitor/ecallantide): ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that binds kallikrein and blocks conversion of high‑molecular‑weight kininogen to bradykinin, directly reducing bradykinin generation and treating symptoms during acute HAE attacks.

Scope note: this document is part 1 of 2 of the policy series and includes clinical background, evidence summaries, society guidelines, and referenced codes for the listed products (Berinert, Ruconest, Kalbitor, Cinryze).

Term	Definition
HAE-1/2
Hereditary angioedema due to C1 inhibitor deficiency or dysfunction (Type I or II)
HAE-unknown
Recurring angioedema attacks refractory to high-dose antihistamines with unknown de-novo mutation(s) and no family history